{"entity":{"id":"nct05128825","kind":"trial","name":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","aka":[],"tldr":"A phase 2 trial of Azenosertib in ovarian cancer, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, now recruiting.","summary":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer is a phase 2 interventional study registered as NCT05128825 by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, with 310 participants planned, started 2022-02-17 and due to reach its primary completion in 2026-12-01. Interventions recorded: azenosertib. Conditions listed: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05128825","url":"https://clinicaltrials.gov/study/NCT05128825"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["azenosertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05128825","phase":"2","setting":"A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","enrolled":310,"outcomes":[]},"route":"/trials/nct05128825/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"azenosertib","kind":"drug","name":"Azenosertib","route":"/drugs/azenosertib/"}]}}